New leaders took over the commercial divisions for Gilead and Bristol-Myers Squibb this week.
BMS promoted its international markets head Christopher Boerner to EVP and chief commercial officer, and Gilead appointed Laura Hamill to EVP of worldwide commercial operations. Both will oversee global commercial activities for the pharma companies.
Hamill comes to Gilead from Amgen, where she served most recently as SVP U.S. commercial operations. She is replacing James Meyers, who retired in February and moved into an advisory role at Gilead.
She spent more than 16 years at Amgen working in strategy for its international markets including Europe, Latin America, the Middle East, Canada, and Australia. She also managed the company’s Inflammation Business Unit and launched its blockbuster autoimmune drug Enbrel. Earlier in her career, Hamill held roles at Hoffmann La-Roche and Klemtner Advertising.
Earlier this month, Gilead also appointed its first chief patient officer, while its chief medical officer, Andrew Cheng, exited the company. Other leadership changes in recent months include the departure of CEO John Milligan, chairman John Martin, and R&D head Norbert Bischofberger.
Boerner, meanwhile, is replacing Murdo Gordon, who left the company in early August and joined Amgen as EVP of global commercial operations. He will report to chairman and CEO Giovanni Caforio.
Boerner has been with BMS since 2015 and served as both U.S. and international head of commercialization. Previously, he led commercial activities for Seattle Genetics and the marketing team for Dendreon. He also worked in various commercial and marketing roles at Genentech earlier in his career.
